Clinical assessment of specific enzyme immunoassay for the XXXX cardiac myosin light chain II (MLC II) with use of monoclonal antibodies.

@entity1 @entity296 @entity908 @entity299 @entity583 @entity121
A highly specific enzyme-linked "sandwich" immunoassay was developed for determining cardiac myosin light chain II (MLC II) in serum by using an anticardiac MLC II monoclonal antibody and a solid phase consisting of glass rods coated with another monoclonal antibody. We can detect as little as 0.2 ng of @entity299 per assay. The measurable range of @entity299 concentration in serum is 1 to 30 micrograms/L. The assay demonstrated no cross-reactivity with a skeletal muscle MLC within the measurable range. The mean coefficients of variation were 6.1% within assay and 5.1% between assay. The concentration of @entity299 in sera from healthy subjects ranged from 0 to 4.0 micrograms/L (mean 0.75 micrograms/L and median 0 micrograms/L). The concentrations of @entity299 in serum of @entity1 with @entity121 due to various causes (n = 15) and @entity1 with effort angina (n = 25), in general, were not significantly elevated above normal. In all @entity1 with @entity583 , the concentrations of @entity299 were over 4.0 micrograms/L at 12 h after onset. The mean (+/- 1 SD) peak concentration of @entity299 was 16.2 (+/- 4.4) micrograms/L at 90 h (mean) after onset. On the 5th day, the @entity299 concentrations in all @entity1 with @entity583 were significantly elevated above normal; none showed abnormal MB- @entity908 kinase (CK-MB) activity at this time. Thus, the measurement of @entity299 concentration in serum may be useful to provide a specific and sensitive diagnosis of @entity296 at any time period following @entity583 .
